Serine/threonine kinase PAK1 is activated by estrogen and plays an important role in breast cancer. However, the integration of PAK1 into the estrogen response is not fully understood. In this study, we investigated the mechanisms underlying the hormone-induced activation of estrogen receptor (ERa, ESR1). We show that estrogen activated PAK1 through both the ERa and GPER1 membrane receptors. Estrogen-dependent activation of PAK1 required the phosphorylation of tyrosine residues by Etk/ Bmx and protein kinase A (PKA) within an assembled signaling complex comprising pTyr-PAK1, Etk/Bmx, the heterotrimer Gprotein subunits Gb1, Gg2, and/or Gg5, PAK-associated guanine nucleotide exchange factor (bPIX, ARHGEF7), and PKA. Moreover, the PKA RIIb subunit is a direct target of PAK1, and thus in response to estrogen, the activated pTyr-PAK1 complex reciprocally potentiated PKA activity, suggesting a positive feedback mechanism. We also demonstrate that PKA phosphorylated Ser305-ERa in response to estrogen, but pTyr-PAK1 phosphorylated Ser305-ERa in response to prolactin (PRL), implying that maximal ERa phosphorylation is achieved when cells are exposed to both PRL and estrogen. Furthermore, S305-ERa activation led to enhanced phosphorylation of Ser118-ERa and promoted cell proliferation and tumor growth. Together, these data strongly support a critical interplay between PRL and estrogen via PAK1 and suggest that ligand-independent activation of ERa through PRL/PAK1 may impart resistance to antiestrogen therapies. Cancer Res; 76(9); 1-12. Ó2016 AACR.
Introduction
Estrogens play a crucial role in regulating the growth and differentiation of breast cancers, with about two thirds of all breast tumors expressing the estrogen receptor a (ERa; ref. 1) . Although the involvement of estrogen in breast cancer tumorigenicity has been known for years, the exact mechanisms are unclear. Estrogen action is mediated by "classical" (initiated in nucleus) and "alternative" (initiated at the plasma membrane) pathways. The "alternative" pathway promotes a fast response to estrogen and is mediated by membrane-localized ERa (mERa) that activates Ga and Gbg proteins, leading to calcium and cyclic AMP (cAMP) generation (2) . Estrogen also signals through Gprotein-coupled receptor 30 [GPR30 or G-protein-coupled ER 1 (GPER1); ref . 3] . GPER1 activation results in the stimulation of both Gas and Gai/o, through which adenylyl cyclase (AC) is either positively or negatively regulated, leading to changes in cAMP level and protein kinase A (PKA) activity. Upon the activation of both mER and GPER1, Ga dissociates from Gbg, and both trigger the activation of downstream effectors (3).
The role of prolactin (PRL) in the pathogenesis of breast cancer is increasingly appreciated (reviewed in refs. 4, 5, 6) . PRL receptor (PRLR) is expressed in many breast cancers, including both ERa þ and ERa À tumors (7) , and PRLR mRNA is elevated in tumors (8) .
Augmented circulating PRL was linked to a 60% increased risk of ER þ tumors (4), and elevated circulating PRL 10 years prior to diagnosis was associated with the risk for metastatic ER þ disease (9) . Circulating PRL and PRL secreted in hyperprolactinemia have been also associated with metastatic breast cancer (10, 11) . In addition, breast cancer tumorigenicity is amplified by PRL produced locally by the breast tumor (12) . In response to PRL, PRLR activates nonreceptor tyrosine kinase JAK2, which activates several signaling cascades, including STATs (13) .
Although PRL and estrogen exert independent effects on breast cancer cells, there is cross-talk between the two hormones that leads to enhanced breast cancer cell proliferation (14) . This crosstalk occurs at multiple levels and is bidirectional in that modulation of the ER pathway influences PRL pathways and vice versa. PRL increases expression and phosphorylation of ERa, and enhances alternative estrogen signaling, while estrogen induces transcription of both PRL and PRLR and potentiates PRL-dependent STAT5 activity (reviewed in ref. 15) . Defining the mechanisms of cross-talk between estrogen and PRL has important implication for treatment of tumor resistance and for identifying new therapeutic targets in breast cancer. Here, we provide evidence that the serine/threonine kinase PAK1 is a common node in PRL and estrogen cross-talk.
The misregulation of PAK1 activity has been demonstrated in many cancers and has been extensively studied in breast cancer (16) . PAK1 directly phosphorylates ERa at Ser305 to promote the transactivation of the receptor, leading to upregulation of cyclin D1. This transactivation may contribute to the development of estrogen-independent growth of breast cancer cells and tamoxifen resistance (17) . However, the role of PAK1 in the respective signaling pathways affected is not defined.
We have discovered previously that PAK1 is a target for PRLactivated JAK2 and that JAK2 phosphorylates PAK1 on tyrosines 153, 201, and 285 (18) . Tyrosyl phosphorylation of PAK1 (pTyr-PAK1) enhances PAK1 kinase activity and its ability to form protein/protein interactions. Both PAK1 activities are important for PRL-dependent breast cancer cell adhesion, motility, and invasion (19, 20, 21) . pTyr-PAK1 also regulates PRL-induced cyclin D1 promoter activity (22) . Similarly to PRL treatment, irradiation of lung cancer cells also leads to the phosphorylation of tyrosines 153, 201, and 285 by JAK2, resulting in increases in PAK1 stability, epithelial-mesenchymal transition, and radioresistance (23) . In addition to JAK2, the nonreceptor tyrosine kinase Etk/Bmx phosphorylates and activates PAK1, leading to increased proliferation of MCF-7 cells (24) .
In this study, we sought to elucidate the mechanism by which estrogen and PRL coactivate ERa and a role of pTyr-PAK1 in this process. We demonstrated that estrogen-activated Etk directly phosphorylated PAK1 on Tyr153. Activated Gbg bound to PAK1 in a complex with Etk and PAK1-associated bPIX to potentiate PKA activation. PKA-Ca directly phosphorylated PAK1, while PKA-RIIb was a direct target of PAK1. We also demonstrated that, in response to estrogen, PKA phosphorylated Ser305-ERa, whereas PRL caused phosphorylation of the same site by PAK1. Our results identified reciprocal relationships between PAK1 and PKA, wherein each activated the other in response to estrogen. Our findings established PAK1 as a new target in both estrogen and prolactin signaling and provide a possible explanation of how these two hormones synergistically regulate breast cancer cell proliferation.
Materials and Methods
Plasmids, antibodies, siRNA, reagents, and inhibitors are described in Supplementary Material and Methods and in Supplementary Table S1 .
Cells
MCF-7 and T47D cell lines were purchased from the ATCC. The following cell lines were kindly donated: TMX2-28 (Dr. Eisenmann, University of Toledo, Toledo, OH); SKBR3 (Dr. Chen, Clemson University, Clemson, SC), HC-11 (Dr. Carter-Su, University of Michigan, Ann Arbor, MI), and MDA-MB-134 and BT474 (Dr. Rae, University of Michigan). All cell lines were authenticated using Promega GenePrint10 System and were grown up for fewer than 6 months following resuscitation. They were routinely verified to be mycoplasma-free using the MycoProbe Mycoplasma Detection Kit (R&D Systems). All cell lines were tested and authenticated in November 2015. MCF-7 clones, SKBR3, HC-11, MDA-MB-134, and BT474 cells were maintained in DMEM (Corning-Cellgro) supplemented with 10% FBS (Sigma-Aldrich). T47D and TMX2-28 clones were maintained as described in refs. 19, 20. Immunoprecipitation, PAK1 in vitro kinase assay, and gene silencing were performed as described in ref. 21 . Briefly, immunoprecipitated PAK1 was subjected to an in vitro kinase assay in the presence of 10 mCi of [g- 32 P]ATP and histone H4 (substrate of PAK1). For siRNA transfection, 100 nmol/L of specific siRNAs [PAK1 and bPIX (Santa Cruz Biotechnology), Etk/Bmx, GPER1, and ERa (Cell Signaling Technology)] were transiently transfected using Lipofectamine RNAiMAX Reagent (Invitrogen) according to the manufacturer's instructions.
PKA kinase assay
Cells were lysed by 5 freeze/thaw cycles. Equal amount of protein was subjected to an in vitro kinase assay in the presence of 5 mCi [g- 32 P] ATP and kemptide (synthetic peptide substrate). Twenty microliters of the reaction volume was spotted on P81 phosphocellulose paper (EMD Millipore) and subjected to liquid scintillation counting (25) .
Cell proliferation assay
The cells were deprived for 24 hours in phenol red-free DMEM supplemented with 1% charcoal-stripped serum, treated with 500 ng/mL PRL or 1 nmol/L 17b-estradiol (E2). Cell proliferation was assessed in 7 days by MTT cell proliferation assay (Life Technologies) according to the manufacturer's instructions (26) .
Treatment with inhibitors
Serum-deprived cells were treated with E2 (1 nmol/L, 30 minutes) in the presence or absence of inhibitors: LY294002 (10 mmol/L, 1 hour); UO126 (10 mmol/L, 1 hour); SB203580 (10 mmol/L, 6 hours); SP600125 (30 mmol/L, 1 hour); AG879 (increasing concentrations, 1 hour); PP1 or PP2, (increasing concentrations, 2 hours); GF109203X (5 mmol/L, 2 hours); IKK inhibitor VII (5 mmol/L, 16 hours); imatinib mesylate (STI 571; increased concentrations, 24 hours); or canertinib (increased concentrations, 4 hours). To inhibit PKA, H89 (10 mmol/L, 1 hour); myristoylated-PKI amide (14-22; myr; 20 mmol/L, 1 hour), Rp-cAMP (100 mmol/L, 2 hours), and 4-cyano-3 methylisoquinoline (4C3MQ; 2 mmol/L, 4 hours) were used. Whole-cell lysates were probed with indicated antibodies. For ETK and Src inhibition, ETK and Src were immunoprecipitated with the aETK and aSrc, respectively, and subjected to in vitro kinase assay.
Etk in vitro kinase assay
HA-PAK1 wild-type (WT)/pCMV6 or PAK1 mutants were translated in vitro using TNT Coupled Reticulocyte Lysate Systems T7 (Promega) with S 
Xenograft model
MCF-7 clones stably overexpressing vector, PAK1 WT, or PAK1 Y3F were inoculated directly into mammary fat pad of NSG (NOD/SCID/IL2Rg) female mice. The mice were supplied with doxycycline (2 mg/mL) in drinking water and implanted with slow-release estradiol pellets. hPRL (20 mg/100 mL) was injected subcutaneously every other day until the end of the experiment. Tumors were measured and volume calculated as V ¼ (4/3) R1 
Statistical analysis
Data from at least three separate experiments were pooled and analyzed using one-way ANOVA plus Tukey honest significant difference test. Differences were considered to be statistically significant at a P < 0.05. Results are expressed as the mean AE SE.
Results and Discussion
Estrogen activates PAK1 in a tyrosyl phosphorylationdependent manner E2 is responsible for the proliferation of normal and neoplastic breast tissue. Because PAK1 also stimulates cell proliferation (16), we tested whether PAK1 overexpression enhances the E2-dependent proliferation of MCF-7 and T47D breast cancer cells. As demonstrated previously, E2 induced proliferation of T47D and MCF-7 cells (Fig. 1A, vector) . PAK1 WT overexpression did not affect basal cell proliferation, and E2 increased cell growth in both lines (Fig. 1A, PAK1 WT cells). In contrast, overexpression of PAK1 Y3F (3 JAK2 phosphorylation sites mutated) strongly decreased E2-dependent cell proliferation relative to PAK1 WT overexpression (Fig. 1A, PAK1 Y3F cells) . Similar results were obtained in BT474, MDA-MB-134, and HC-11 cell lines ( Supplementary Fig.  S1A ), indicating that this finding was not restricted to MCF-7 and T47D cells. To confirm the role of PAK1 in cell proliferation, we treated control MCF-7 and T47D cells with PAK1 inhibitor IPA-3 (Supplementary Fig. S1B ; ref. 27 ). IPA-3 did not inhibit proliferation of vehicle-treated cells and was not toxic but it did inhibit E2-dependent cell proliferation in a concentration-dependent manner ( Supplementary Fig. S1C ), confirming that PAK1 participates in E2-dependent cell proliferation.
To uncover the mechanism by which pTyr-PAK1 regulates E2-dependent cell proliferation, we assessed PAK1 kinase activity in E2-treated cells, because E2 activates PAK1 (28) . As demonstrated previously, PRL activated PAK1 WT significantly stronger than PAK1 Y3F confirming that tyrosines 153, 201, and 285 are required for full activation (Fig. 1B, left; refs. 19, 20) . PAK1 WT activation by E2 or PRL was similar. Surprisingly, E2 failed to activate PAK1 Y3F (Fig. 1B, right) . In addition, E2-induced phosphorylation of Thr423-PAK1 (a marker of PAK1 activation) was detected in PAK1 WT, but not in PAK1 Y3F cells ( Supplementary  Fig. S1D ), demonstrating that PAK1 tyrosyl phosphorylation is important for E2-dependent PAK1 activation. To confirm that PAK1 Y3F retains its kinase activity, we assessed the effect of heregulin (HRG), a known activator of PAK1 (29), on PAK1 activation. HRG-induced PAK1 kinase activity was similar in cells expressing PAK1 WT and PAK1 Y3F (Fig. 1C) , confirming that PAK1 Y3F is functionally active.
Etk kinase directly phosphorylates and activates PAK1 in response to estrogen
To understand how E2 mediated PAK1 tyrosyl phosphorylation and activation, we tested whether E2 activates JAK2. As expected, PRL, but not E2, strongly activated JAK2 (Supplementary Fig. S2A ). We hypothesized that kinase(s) other than JAK2 tyrosyl phosphorylated PAK1 in response to E2 and tested Etk/ Bmx, Src, c-Abl, and ErbB because they have been previously implicated in tyrosyl phosphorylation of either PAK1 or PAK2 (24, 30, 31, 32) . Inhibition of c-Abl by STI571 and ErbB by canertinib did not affect E2-dependent PAK1 tyrosyl phosphorylation, although Erk 1/2 activation was eliminated by both inhibitors ( Supplementary Fig. S2B ). Similarly, Src inhibitors PP1 and PP2 did not affect E2-dependnet PAK1 tyrosyl phosphorylation but blocked Src activation ( Supplementary Fig. S2C ).
AG879 inhibition of Etk resulted in a concentration-dependent decrease in pTyr-PAK1 ( Fig. 2A, left) , suggesting that Etk is involved in E2-dependent PAK1 phosphorylation. Tyrosines 153, 201, and 285 are implicated in this E2-dependent phosphorylation because Y3F was not phosphorylated in response to neither PRL nor E2 ( Fig. 2A, right) . More importantly, Etk inhibition attenuated E2-dependent PAK1 kinase activity (Fig. 2B ). To support this finding, we knocked down Etk by siRNA and assessed E2-dependent PAK1 activity. Indeed, Etk silencing decreased E2-dependent PAK1 activity (Fig. 2C) . We recovered E2-dependent PAK1 activation by reintroducing WT, but not kinase-dead Etk (33) , in the Etk-depleted cells (Fig. 2C ). These data strongly suggest that Etk tyrosyl phosphorylates and activates PAK1 in Etk directly phosphorylates and activates PAK1 in response to estrogen. A, PAK1 WT cells were treated with Etk inhibitor AG879 (AG) before E2 treatment and immunoprecipitated (IP) PAK1, or whole-cell lysates (WCL) were probed with antibodies (left). PAK1 or JAK2 were immunoprecipitated from PAK1 WT and Y3F clones treated with E2 or PRL and immunoblotted (right). B, cells were treated with AG879. PAK1 was immunoprecipitated and subjected to an in vitro kinase assay as in Fig. 1 . C, cells were transfected with control (scr) or Etk siRNA. In siRNA rescue experiments, 24 hours after Etk siRNA transfection, cells were transfected with either Etk WT or Etk kinase-dead mutant (KD). PAK1 was immunoprecipitated and subjected to in vitro kinase assay as in Fig. 1 (Fig. 2D) . To map PAK1 phosphorylation site(s), we performed in vitro kinase assays using recombinant Etk and in vitro-translated PAK1 WT, Y3F, Y153F, Y201F, Y285F, or Y55F PAK1 mutants. Etk failed to phosphorylate both PAK1 Y3F and Y153F (Fig. 2E) . To show that Etk phosphorylates Tyr-153 of PAK1 in response to E2, we immunoprecipitated overexpressed Etk WT or kinase-dead Etk from MCF-7 cells treated with/without E2 and assessed kinase activity in vitro with in vitrotranslated PAK1 WT and Y153F. As expected, E2-activated Etk directly phosphorylated PAK1 WT, but not Y153F (Fig. 2F) . Our data strongly suggest that E2-activated Etk directly phosphorylates PAK1 WT on Tyr 153, causing PAK1 activation.
Although the mechanisms by which estrogen receptors regulate Etk kinase need to be further investigated, we speculate that Etk may be an effector of Gbg subunits in response to E2 (see below).
E2 promotes PAK1 activation through both ERa and GPER1 plasma membrane receptors
The rapid activation of PAK1 by E2 (Fig. 1B) indicates involvement of either mER and/or GPER1. These two estrogen-responsive receptors are structurally different and can trigger different signaling pathways in the same cell, including MCF-7 cells (34, 35, 36) . Both GPER1 and mERa are involved in estrogen-dependent PAK1 activation. A and B, MCF-7 and TMX2-28 cells were treated with E2 and either whole-cell lysates were probed with indicated antibodies (A) or in vitro kinase assay was performed (B). C and D, MCF-7 and SKBR3 cells were treated with E2 and either whole-cell lysates were probed with the indicated antibodies (C) or in vitro kinase assay was performed (D). E, MCF-7 PAK1 WT cells were transfected with control (scr), ERa, GPER1 (GPR), or ERaþGPER1 (ER/G) siRNAs. HA-PAK1 was immunoprecipitated and subjected to in vitro kinase assay. F, TMX2-28 PAK1 WT cells were transfected cDNAs encoding GPER1 (GPR), ERa, or ERaþGPER1 (ER/G). HA-PAK1 was immunoprecipitated and subjected to the in vitro kinase assay. HA, hemagglutinin; vec, vector; veh, vehicle.
Ã , P < 0.05, n ¼ 3. (Fig. 3A) . Furthermore, TMX2-28 cells are also GPER1 deficient (Fig. 3A) . E2 activated PAK1 in MCF-7 cells, but not in TMX2-28 cells, whereas PRL activated PAK1 similarly in both lines (Fig. 3B) , suggesting that either mERa or GPER1 are required for E2-dependent PAK1 activation.
To determine whether E2 activates PAK1 via GPER1, we employed ER À /GPER1 þ SKBR3 cells. E2 activated GPER1 in both MCF-7 and SKBR3 cells as demonstrated by Erk1/2 phosphorylation, whereas E2 activated ERa only in MCF-7 cells (Fig. 3C ). E2 activated PAK1 in both lines, suggesting that GPER1 participates in PAK1 activation (Fig. 3D) . To confirm this observation, we performed siRNA knockdown of either GPER1, ERa, or both receptors in MCF-7 cells. Silencing of either ERa or GPER1 significantly decreased E2-triggered PAK1 activation; however, only downregulation of the ERa and GPER1 together completely abolished E2-dependent PAK1 activation (Fig. 3E) . We also overexpressed GPER1, ERa, or both receptors in TMX2-28 cells and showed that E2 caused maximal PAK1 activation when both GPER1 and ERa were present (Fig. 3F ). These data suggest that E2 promotes PAK1 activation through both mERa and GPER1 plasma membrane receptors.
Gbg subunits of G-protein activate PAK1 in response to estrogen mERa and GPER1 activate heterotrimeric G-proteins (3). The Gbg dimer directly binds to both PAK1 (38) and E2-activated mERa (39) . To determine which combination of b and g subunits participates in E2-dependent PAK1 activation, we overexpressed b1 or b2 together with g2, g5, or g13 in different combinations and assessed E2-dependent PAK1 activity (Fig. 4A) . As expected, E2 activated PAK1 (lane 2 vs. lane 1). b1g2 and b1g5 overexpression strongly enhanced E2-dependent PAK1 activity (lanes 4 and 6). Interestingly, b2g2 (lane 8), b2g5 (lane 10), or b1g13 (lane 12) overexpression inhibited E2-dependent PAK1 activity, whereas b2g13 (lane 14) overexpression had no effect compared with control (lane 2). To test whether PAK1 tyrosines play a role in activation, we overexpressed b1g2 and b1g5 subunits in PAK1 WT and Y3F clones and assessed E2-dependent PAK1 activation. b1g5 overexpression increased both basal and E2-stimulated PAK1 WT activity (Fig. 4B, lanes 5-6) , whereas b1g2 overexpression enhanced PAK1 WT activity only in response to E2 (lanes 3-4) . b1g2 and b1g5 overexpression did not activate PAK1 Y3F (lanes 9-12), whereas HRG strongly activated PAK1 WT and Y3F (lanes [13] [14] . To assess PAK1 binding to b1g2 and b1g5, PAK1 WT or Y3F were immunoprecipitated and assessed for b1g2, b1g5 (Fig.  4C), and b1g13 (Supplementary Fig. S2D ). PAK1 WT bound to E2-activated b1g2 and to b1g5 independent of E2 ( Fig. 4C and Supplementary Fig. S2D, lanes 3-6) . We considered PAK1 WT binding to b1g2 without E2 (Fig. 4C and Supplementary Fig. S2D , Supplementary Fig. S2D, lanes 1-2) and Y3F to b1g13, b1g2, and b1g5 ( Fig. 4C and S2D ) as negligible. Endogenous Etk was associated with E2-activated PAK1 WT (aEtk blot, lanes 2, 4, and 6 in Fig. 4C and Supplementary Fig. S2D ), while PAK1 Y3F failed to bind to Etk (lanes 7-12). These data suggest that E2 treatment promotes the formation of Gb1g2,5/PAK1/Etk complex.
PAK1 can be activated by b1g2 or b1g5 subunits via the PI3K and Akt pathways independently of Rac1 or Cdc42 (40) . In that study, EGF, PMA, LPA, and carbachol did not augment PAK1 activity beyond that induced by b1g2 or b1g5 (40) . Our data demonstrated additive effect of E2 underlying a high degree of specificity for this pathway.
bPIX facilitates E2-dependent PAK1 activation
In response to chemoattractants, Gbg binds directly to PAK1, which simultaneously associates with aPIX (PAK-associated guanine nucleotide exchange factor) to form a Gbg/PAK1/aPIX/ Cdc42 complex, leading to PAK1 activation (38) . Because we have previously shown that PRL increases association of bPIX with PAK1 WT but not Y3F and Y285F mutants (21), we reasoned that formation of the Gbg/PAK1/bPIX complex plays a role in E2-dependent PAK1 activation. We immunoprecipitated PAK1 from E2-treated PAK1 WT and Y3F cells and probed for endogenous bPIX. E2 increased bPIX association with PAK1 WT but not with Y3F (Fig. 5A) , demonstrating that tyrosyl phosphorylation of PAK1 facilitates E2-dependent binding with bPIX. We next overexpressed bPIX in WT and Y3F clones and assess E2-dependent PAK1 kinase activity. bPIX significantly activated PAK1 WT versus Y3F in response to E2 (Fig. 5B) . bPIX silencing abolished E2-dependent PAK1 activation (Fig. 5C, lane 3) , while reexpression of bPIX WT rescued PAK1 activation (lane 4). Reexpression of bPIX DHm(L238R/L239S), lacking guanine nucleotide exchange (GEF) activity, partially rescued PAK1 kinase activity (lane 5), and reexpression of bPIX SH3m(W43K), which lacks PAK1 binding activity, did not (lane 6). These data suggest that bPIX binding to PAK1 is required for its activation and that bPIX GEF activity is sufficient for E2-dependent PAK1 activation. Furthermore, PAK1 tyrosyl phosphorylation is also required for E2-dependent bPIX binding. To test whether bPIX is a member of Gb1g2,5/PAK1/Etk complex, we immunoprecipitated either WT or Y3F from cells treated with/without E2 and blotted for bPIX. bPIX was associated with E2-activated PAK1 WT (Fig. 4C and Supplementary Fig. S2D , abPIX blot, lanes 2, 4, and 6). PAK1 Y3F complexed with b1g5 only, and independently of E2 (lanes 11-12). E2 also promotes formation of this Etk/PAK1/bPIX complex in T47D, BT474, MDA-MB-134, and HC-11 cells (Supplementary Fig. S3A ). These data suggest that E2 induces a multiprotein signaling complex containing pTyr-PAK1, Etk, b1/g2, or b1/g5 subunits and bPIX. It appears that three tyrosines of PAK1 are required for the formation of this complex, which facilitates PAK1 activation.
E2-dependent PKA activity is reciprocally regulated by activated pTyr-PAK1
E2 rapidly activates multiple signaling pathways, including MAPKs, PI3K, PKC, PKA, NFkB, and Src (2). To determine which of these pathways are implicated in E2-triggered PAK1 activation, we treated MCF-7 cells with E2 and selective inhibitors. Inhibitor specificity was confirmed ( Supplementary Fig. S4A ), and all inhibitors had no effect on PAK1 activity in vehicle-treated cells, demonstrating that they did not independently effect PAK1 activity ( Supplementary Fig. S3B ). Only PKA inhibition by H89 inhibited E2-dependent PAK1 kinase activity (Fig. 6A) . To confirm that the effect of H89 was specific to estrogen, we treated PAK1 WT cells with PRL þ H89 and showed that PAK1 kinase activity was unaffected (Supplementary Fig. S3C ). In addition to H89, other selective PKA inhibitors, myristoylated-PKI amide (14-22; myr), Rp-cAMP, and 4-cyano-3 methylisoquinoline (4C3MQ; Supplementary Fig. S4B ) also inhibited E2-activated PAK1 (Fig. 6B) . Furthermore, PAK1 activity was enhanced by forskolin, which triggers general cAMP elevation and PKA activation, and abolished by Rp-cAMP (Fig. 6B) .
In response to E2, both mERa and GPER1 activate Gas, leading to the stimulation of AC, cAMP, and the subsequent activation of PKA (2, 3) . PKA is a PAK1 regulator in anchorage-dependent signal transduction (41) . PKA phosphorylates bPIX, leading to activation of PAK1 effector, Cdc42 (42) . Furthermore, PKA phosphorylates PAK1 and the PKA catalytic subunit phosphorylates and complexes with PAK1/4 (41, 43, 44) . Hence, we hypothesized that activated PAK1 may in turn modulate PKA activity. PKA in vitro kinase activity was significantly elevated in E2-treated, but not in RPL-treated, PAK1 WT cells (Fig. 6C) . Interestingly, PAK1 Y3F inhibited E2-triggered PKA activation (Fig. 6C) . To study whether the formation of Gb1g2/Etk/PAK1/ bPIX complex facilitates E2-dependent PKA activation, we overexpressed these proteins in PAK1 WT cells and assessed endogenous PKA in vitro kinase activity. PKA activity was maximal when b1g2, Etk, PAK1, and bPIX were present and E2 was added (Fig.  6D) . To determine which PKA subunit complexed with PAK1, different PKA subunits were overexpressed in PAK1 WT cells, treated with/without E2. PKA-RIIb subunit interacted with PAK1 WT in E2-independent manner (Fig. 6E) . To demonstrate that PKA RIIb is a direct substrate of PAK1, we assessed in vitro translated HA-PAK1 with immunoprecipitated PKA-RIIb in the in vitro kinase assay. Translated PAK1 was active as judged by the in vitro phosphorylation of H4 histone (PAK1 substrate, Fig. 6F , lane 4) and PAK1 directly phosphorylated RIIb (Fig. 6F, lane 5) . In agreement with published data (41), in vitro-translated PAK1 was directly phosphorylated by recombinant active PKA-Ca (catalytic subunit) in the in vitro kinase assay (Fig. 6G ). These data suggest that PKA-Ca directly phosphorylates PAK1, while PKA-RIIb is the direct target of PAK1. In response to E2, activated pTyr-PAK1 complexes with b1g2/Etk/bPIX to potentiate PKA activation. At the same time, PKA is required for full E2-dependent PAK1 activation, demonstrating positive feedback between these two kinases.
PKA phosphorylates Ser305-ERa in response to E2 and PAK1 phosphorylates Ser305-ERa in response to PRL Ser305-ERa can be phosphorylated by PAK1 and PKA (45, 46) . Constitutively active PAK1 phosphorylates Ser305-ERa, resulting in subsequent phosphorylation of Ser118-ERa, ligand-independent ER activation, and tamoxifen resistance (45, 47) . PAK1 overexpression increased phosphorylation of both Ser305-ERa and Ser118-ERa upon E2 treatment (Fig. 7A, lanes 3 vs. 7 , white and black bars), whereas Y3F overexpression inhibited pSer118-ERa (Fig. 7A, lanes 11 vs. 3) . PRL treatment induced Ser305-ERa, but not Ser118-ERa phosphorylation, in WT PAK1 cells but had no effect in Y3F cells (Fig. 7A, lanes 2, 6 and 10) .
Next, we aimed to determine whether PAK1 or PKA participate in E2-and PRL-triggered ERa phosphorylation. PAK1 siRNA silencing abolished PRL-dependent Ser305-ERa phosphorylation, but not E2-dependent Ser305-ERa phosphorylation (Fig.  7B, lanes 2 vs. 4) . To confirm that PAK1 phosphorylates Ser305-ERa in response to PRL, we reintroduced PAK1 into PAK1-silenced cells and recovered PRL-dependent Ser305-ERa phosphorylation (Fig. 7C) . To test whether PKA phosphorylates Ser305-ERa in response to E2, we inhibited PKA by Rp-cAMPs and observed that pSer305-ERa signal was strongly decreased in the cells treated with E2 or forskolin (Fig. 7D, lanes 3 vs. 8 and 5 vs. 10), but not in the cells treated with PRL or PRL þ E2 (Fig. 7D,  lanes 2 vs. 7 and 4 vs. 9 ).
These data suggest that PKA phosphorylates Ser305-ERa in response to E2, while PAK1 phosphorylates Ser305-ERa in response to PRL. PAK1 augments PKA-dependent Ser305-ERa phosphorylation, as PAK1 overexpression significantly increased E2-dependent Ser305-ERa phosphorylation (Fig. 7A, lines 7 vs. 3). Furthermore, PAK1 tyrosines 153, 201, and 285 participate in both signaling pathways because Y3F overexpression inhibited Ser305-ERa phosphorylation after both PRL and E2 treatments (Fig. 7A, lanes 10-12) . As PAK1 WT, but not Y3F, significantly enhanced E2-dependent PKA activation (Fig. 6D) , our data suggest that although PAK1 does not phosphorylate Ser305-ERa upon E2 treatment, it augments PKA activation and subsequent Ser305-ERa phosphorylation, indirectly increasing estrogen responsiveness. (Fig. 7A, lanes 8 vs. 7 and 6 ). S305-ERa phosphorylation by PAK1 promotes ERa transactivation, leading to upregulation of cyclin D1 and hormone-independence (48) . To determine whether enhanced ERa activation impacted breast cancer cells, we evaluated the effect of PRL þ E2 on proliferation. In agreement with published studies demonstrating that PRL enhances E2-induced proliferation (14, 49, 50, 51,52), PRL þ E2 induced proliferation of control MCF-7 cells (Fig. 7E, vector) . PAK1 overexpression further enhanced cell proliferation in response to E2 þ PRL as compared with cells treated with either PRL or E2 (Fig. 7E, PAK1 WT cells) . In contrast, Y3F inhibited E2 þ PRL-dependent proliferation (PAK1 Y3F cells), implicating these tyrosines in PAK1 regulation. To demonstrate that the role of PAK1 in synergistic PRL þ E2-mediated signaling is not limited to MCF-7 cells, we assessed proliferation of different human breast cancer cell lines endogenously expressing PRLR and ER (T47D, BT474, and MDA-MB-134), as well as mouse mammary HC-11 cells. In all lines, PAK1 overexpression enhanced cell proliferation in response to E2 þ PRL, compared with the cells treated with either PRL or E2 (Supplementary Fig.  S5 ). Finally, PRL þ E2-activated pTyr-PAK1 enhances breast tumor growth in a xenograft mouse model (Fig. 7F) .
Synergistic effects of PRL and
We have demonstrated here that tyrosines 153, 201, and 285 play a role in PAK1 activation by E2 (but not HRG), ability of PAK1 to complex with Gb1g2 and 5, Etk, and bPIX, activate PKA, phosphorylate S305-ERa, and, finally, enhance PRL þ E2-dependent proliferation and tumor growth. Kim and colleagues have proposed that tyrosyl phosphorylation of these sites may disrupt the inhibitory conformation of PAK1 and/or maintain PAK1 active conformation because Tyr153 resides nearby Ser144 and Ser149, Tyr201 locates near Ser199 and Ser204 (autophosphorylation sites), and Tyr285 lies in the kinase domain and may stabilize the interaction between K299 and ATP molecules (23) . Although it should be confirmed by structural studies, this proposition is very attractive. Another possibility is that pTyr-PAK1 may create additional docking sites to recruit SH2 domain-containing proteins to facilitate PAK1 functions. Either way, these tyrosine phosphorylation events are critical for PAK1 functions.
On the basis of our finding and previous studies, we propose a model for PAK1 in estrogen-and PRL-triggered intracellular signaling, leading to a synergistic effect of PRL and E2 on Ser305-ERa phosphorylation, cell proliferation, and tumor growth (Fig. 7G) . E2 activates mERa and GPER1, leading to Gprotein activation that dissociates into a and bg subunits, both of which activate additional effectors. Gas activates PKA, which can phosphorylate many substrates, including PAK1 and Ser305-ERa. In addition, b1g2 and b1g5 are released and bind to PAK1, which is directly phosphorylated by Etk on Tyr153. pTyr-PAK1 recruits and binds to bPIX, an association that further activates PAK1.
Although PKA is the main kinase phosphorylating Ser305-ERa in response to E2, PKA is reciprocally regulated by activated PAK1 as a component of b1g2/Etk/bPIX/pTyr-PAK1 complex. If cells are exposed to both PRL and E2, Ser305-ERa is phosphorylated by Figure 7 . Ser305-ERa is phosphorylated by PKA in response to E2 and by PAK1 in response to PRL. A, control, PAK1 WT, or PAK1 Y3F clones of MCF-7 cells were treated with vehicle, E2, PRL, or PRL þ E2 and whole-cell lysates were immunoblotted. B, cells were transfected with control (scr) or PAK1 siRNA, treated with PRL, E2, or PRL þ E2, and whole-cell lysates were immunoblotted. C, in siRNA rescue experiments, 24 hours after PAK1 siRNA transfection, cells were transfected with control or PAK1 WT, treated with PRL, and whole-cell lysates were immunoblotted. D, cells were incubated with either vehicle or Rp-cAMP, treated with vehicle, PRL, E2, PRL þ E2, or forskolin. E, MCF-7-overexpressing vector, PAK1 WT, or PAK1 Y3F were incubated with vehicle, PRL, E2, or PRL þ E2 and assessed for cell proliferation as in Fig. 1 . F, pTyr-PAK1 accelerates tumor growth in vivo. MCF-7 clones were injected into the mammary pad of female NSG mice. Mice were treated with PRL þ E2. Ã , P < 0.05 compared with control (vector) mice, n ¼ 8. G, proposed mechanisms for the role of PAK1 in synergetic effects of PRL and E2 on ERa activation. E2 activates mERa and GPER1, leading to G-protein and Etk kinase activation. E2-activated Etk binds to and directly phosphorylates PAK1 on Tyr153. Gbg subunits also bind to pTyr-PAK1, facilitating recruitment and activation of bPIX, which in turn binds and further activates PAK1 and establishes a self-amplifying cascade. Gas subunit activates PKA, which binds to PAK1 via PKA-RIIb, while PKA-Ca directly phosphorylates PAK1. Gbg/Etk/pTyr-PAK1/bPIX complex reciprocally activates PKA in response to E2 and activates PKA phosphorylates Ser305-ERa, leading to enhanced S118-ERa phosphorylation. PRL-activated JAK2 phosphorylates and activates PAK1, which also activates ERa by phosphorylation of S305-ERa. Thus, in response to E2 þ PRL, pS305-ERa is phosphorylated by both PAK1 and PKA, which leads to enhanced cell proliferation. fskl, forskolin; vec, vector; veh, vehicle.
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Cancer Research OF10 (46, 47) , and finally induces cell proliferation. E2-dependent Etk and PRL-dependent JAK2 PAK1 tyrosyl phosphorylation are important, as PAK1 Y3F fails to establish this selfamplifying cascade and promote cell proliferation and tumor growth.
Another notable finding is that Ser305-ERa is phosphorylated by PAK1 in response of PRL in the absence of estrogen. Ser305-ERa phosphorylation was implicated in tamoxifen resistance, and a correlation between high level of PAK1 and tamoxifen sensitivity in breast cancer patients is described in refs. 47, 53. Our data predict that patients with augmented levels of PRL will likely develop tamoxifen resistance due to Ser305-ERa phosphorylation by PRL-activated PAK1. Furthermore, the synergistic effects of estrogen and PRL signaling described here are physiologically and therapeutically relevant as breast cells are constantly exposed to both hormones, but anti-estrogen therapy targets only the estrogen component. We introduce PAK1 as a common node for estrogen-and PRL-dependent pathways, making it an attractive target for anticancer therapy.
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